Secukinumab improves symptoms in large psoriatic arthritis trial

Self-administered subcutaneous secukinumab inhibits radiographic progression of psoriatic arthritis better than placebo, according to the largest clinical trial of a biologic for psoriatic arthritis.

In the double-blinded study, nearly 1000 patients were randomised to placebo or one of three treatment arms with secukinumab (Cosentyx, Novartis), a  human monoclonal antibody that inhibits interleukin-17A.

At 16 weeks, 56-63% of patients in the secukinumab arms had achieved the primary endpoint – an American College of Rheumatology 20% response (ACR20) –